Gender-specific links between hepatic 11β reduction of cortisone and adipokines

Obesity

Volumn 15, Issue 4, 2007, Pages 887-894

  Mattsson, Cecilia ^a   Rask, Eva ^a   Carlström, Kjell ^b   Andersson, Jonas ^a   Eliasson, Mats ^c   Ahrén, Bo ^d   Söderberg, Stefan ^a   Olsson, Tommy ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c SUNDERBY HOSPITAL   (Sweden)

^d LUND UNIVERSITY   (Sweden)

Author keywords

11 hydroxysteroid dehydrogenase type 1; Adipocytokines; Gender; Insulin sensitivity; Liver

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; CORTISONE; CYTOKINE; INSULIN; LEPTIN; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; ADULT; ARTICLE; FEMALE; GENE EXPRESSION REGULATION; HUMAN; LIVER; MALE; METABOLISM; MIDDLE AGED; SEX DIFFERENCE;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ADIPOSE TISSUE; ADULT; CORTISONE; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INSULIN; LEPTIN; LIVER; MALE; MIDDLE AGED; SEX FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34248368516     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2007.587     Document Type: Article

References (37)

1. Rask E, Walker BR, Söderberg S, et al. Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11beta-hydroxysteroid dehydrogenase type I activity. J Clin Endocrinol Metab. 2002;87:3330-6.
2. Rask E, Olsson T, Söderberg S, et al. Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab. 2001;86:1418-21.
3. Lindsay RS, Wake DJ, Nair S, et al. Subcutaneous adipose 11beta-hydroxysteroid dehydrogenase type 1 and messenger ribonucleic acid levels are associated with adiposity and insulinemia in Pima Indians and Caucasians. J Clin Endocrinol Metab. 2003;88:2738-44.
4. Seckl J, Morton NM, Chapman KE, Walker BR. Glucocorticoid and 11beta-hydroxysteroid dehydrogenase in adipose tissue. Recent Prog Horm Res. 2004;59:359-93.
5. Low SC, Chapman KE, Edwards CRW, Wells T, Robinson ICAF, Seckl JR. Sexual dimorphism of hepatic 11β-hydroxysteroid dehydrogenase in the rat: the role of growth hormone patterns. J Endocrinol. 1994;143:541-8.
6. Friedberg M, Zoumakis E, Hiroi N, Bader T, Chrousos G, Hochberg Z. Modulation of 11β-hydroxysteroid dehydrogenase type 1 in mature human subcutaneous adipocytes by hypothalamic messengers. J Clin Endocrinol Metab. 2003;88:385-93.
7. Vierhappen H, Nowotny P, Waldhausl W. Urinary steroid excretion rates in acromegaly. Horm Res. 2005;63:234-7.
8. Liu Y, Nakagawa Y, Wang Y, et al. Leptin activation of corticosterone production in hepatocytes may contribute to the reversal of obesity and hyperglycemia in leptin-deficient ob/ob mice. Diabetes. 2003;52:1409-16.
9. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237:E214-23.
10. Slaats EH, Kennedy JC, Kruiswijk H. Interference of sex hormone-binding globulin in the 'Coat-a-Count' testosterone no-extraction radioimmunoassay. Clin Chem. 1987;33:300-2.
11. Masters AM, Hähnel R. Investigation of sex-binding hormone-binding globulin interference in direct radioimmunoassays of testosterone and estradiol. Clin Chem. 1989;35:979-84.
12. Wake DJ, Rask E, Livingstone DE, Söderberg S, Olsson T, Walker BR. Local and systemic impact of transcriptional up-regulation of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity. J Clin Endocrinol Metab. 2003;88:3983-8.
13. Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science. 2001;294:2166-70.
14. Masuzaki H, Yamamoto H, Kenyon CJ, et al. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest. 2003;112:83-90.
15. Paterson JM, Morton NM, Fievet C, et al. Metabolic syndrome without obesity: hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci USA. 2004;101:7088-93.
16. Johansson Å, Andrew R, Forsberg H, Cederquist K, Walker BR, Olsson T. Glucocorticoid metabolism and adrenocortical reactivity to ACTH in myotonic dystrophy. J Clin Endocrinol Metab. 2001;86:4276-83.
17. Krentz AJ, Clark PM, Cox L, Williams AC, Nattrass M. Hyperproinsulinaemia in patients with myotonic dystrophy. Diabetologia. 1992;35:1170-2.
18. Perseghin G, Caumo A, Arcelloni C, et al. Contribution of abnormal insulin secretion and insulin resistance to the pathogenesis of type 2 diabetes in myotonic dystrophy. Diabetes Care. 2003;26:2112-8.
19. Perseghin G, Comola M, Scifo P, et al. Postabsorptive and insulin-stimulated energy and protein metabolism in patients with myotonic dystrophy type 1. Am J Clin Nutr. 2004;80:357-64.
20. Arner P. Insulin resistance in type 2 diabetes: role of the adipokines. Curr Mol Med. 2005;5:333-9.
21. Moller DE, Kaufman KD. Metabolic syndrome: a clinical and molecular perspective. Ann Rev Med. 2005;56:45-62.
22. Wallace AM, McMahon AD, Packard CJ, et al. Plasma leptin and the risk of cardiovascular disease in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 2001;104:3052-6.
23. Söderberg S, Stegmayr B, Stenlund H, et al. Leptin but not adiponectin, predicts stroke in males. J Intern Med. 2004;256:128-36.
24. Piemonti L, Calori G, Mercalli A, et al. Fasting plasma leptin, tumor necrosis factor-α receptor 2, and monocyte chemoattracting protein 1 concentration in a population of glucose-tolerant and glucose-intolerant women. Diabetes Care. 2003;26:2883-9.
25. Friedman JM. Modern science versus the stigma of obesity. Nat Med. 2004;10:563-9.
26. Unger RH. The physiology of cellular liporegulation. Annu Rev Physiol. 2003;65:333-47.
27. Basu R, Singh RJ, Basu A, et al. Splanchnic cortisol production occurs in humans: evidence for conversion of cortisone to cortisol via the 11-beta hydroxy steroid dehydrogenase (11beta-hsd) type 1 pathway. Diabetes. 2004;53:2051-9.
28. Andrew R, Westerbacka J, Wahren J, Yki-Järvinen H, Walker BR. The contribution of visceral adipose tissue to splanchnic cortisol production in healthy humans. Diabetes. 2005;54:1364-70.
29. Jamieson PM, Nyirenda MJ, Walker BR, Chapman KE, Seckl JR. Interactions between estradiol and glucocorticoid regulators effects on liver-specific glucocorticoid-inducible genes: possible evidence for a role of hepatic 11beta-hydroxysteorid dehydrogenase type 1. J Endocrinol. 1999;160:103-9.
30. Gupta S, Alfaidy N, Holloway AC, et al. Effects of cortisol and oestradiol in hepatic 11β-hydroxy steroid dehydrogenase type 1 and glucocorticoid receptor proteins in late-gestational sheep fetus. J Endocrinol. 2003;176:175-84.
31. Diez-Ruiz A, Tilz GP, Zangerle R, Baier-Bitterlich G, Wachter H, Fuchs D. Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. Eur J Haematol. 1995;54:1-8.
32. Mohamed-Ali V, Goodrick S, Bulmer K, Holly JMP, Yudkin JS, Coppack SW. Production of soluble tumor necrosis factor receptors by human subcutaneous adipose tissue in vivo. Am J Physiol Endocrinol Metab. 1999;40:E971-5.
33. Hube F, Birgel M, Lee Y-M, Hauner H. Expression pattern of tumour necrosis factor receptors in subcutaneous and omental human adipose tissue: role of obesity and non-insulin-dependent diabetes mellitus. Eur J Clin Invest. 1999;29:672-8.
34. van Dielen FMH, van't Veer C, Schols AM, Soeters PB, Buurman WA, Greve JW. Increased leptin concentration correlate with increased concentrations of inflammatory markers in morbidly obese individuals. Int J Obes Relat Metab Disord. 2001;25:1759-66.
35. Tomlinson JW, Moore J, Cooper MD, et al. Regulation of expression of 11beta-hydroxysteroid dehydrogenase dehydrogenase type 1 in adipose tissue: tissue-specific induction by cytokines. Endocrinology. 2001;142:1982-9.
36. Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab. 2003;88:2404-11.
37. Cohen PG. Estradiol induced inhibition of 11beta-hydroxysteroid dehydrogenase 1: an explanation for the postmenopausal hormone replacement therapy effects. Med Hypotheses. 2005;64:989-91.